Mount Sinai Deploys AI Platform for Systemwide Cancer Clinical Trial Matching

The platform, called PRISM, was developed by AI company Triomics and is powered by its oncology-focused large language model pipeline, OncoLLM.

The Mount Sinai Tisch Cancer Center (TCC) has launched an artificial intelligence (AI)-powered clinical trial-matching platform designed to connect cancer patients across the Mount Sinai Health System with relevant research studies, the institution said on January 8.

The platform, called PRISM, was developed by AI company Triomics and is powered by its oncology-focused large language model pipeline, OncoLLM. Mount Sinai is the first National Cancer Institute (NCI)-designated Comprehensive Cancer Center in New York City to deploy an oncology-specific AI platform for systemwide clinical trial matching.

PRISM is designed to analyze electronic health records, diagnoses, and clinical characteristics to identify trial eligibility earlier in a patient’s care journey. The tool aims to reduce reliance on manual chart reviews, a process that traditionally requires clinicians and research teams to sift through lengthy trial protocols and fragmented patient records.

“Clinical trials are essential to advancing cancer care, but too often patients and their treating physicians are not aware of studies that may be appropriate for them,” said Karyn Goodman, MD, MS, Professor and Vice Chair of Clinical Research in the Department of Radiation Oncology at the Icahn School of Medicine at Mount Sinai and Associate Director of Clinical Research at TCC. She added that an oncology-trained AI platform can help identify trial opportunities more consistently and allow clinicians to focus on patient discussions rather than administrative screening tasks.

Clinical trial participation has historically been concentrated at major academic hospitals, often limiting access for patients treated at community or satellite sites. With PRISM’s systemwide deployment, patients receiving care at Mount Sinai Queens, Mount Sinai Brooklyn, Mount Sinai South Nassau, Mount Sinai Morningside, Mount Sinai West, and other facilities will be evaluated for available trials using the same infrastructure as those treated at The Mount Sinai Hospital.

Mount Sinai said the initiative aligns with its role as an NCI-designated Comprehensive Cancer Center by expanding access to clinical research across care settings and integrating research opportunities earlier in routine oncology workflows. The systemwide approach is expected to increase the number of patients considered for trials and support more equitable access to investigational therapies.

The deployment was carried out in collaboration with Triomics, the Tisch Cancer Center, and Mount Sinai Research IT. The health system plans to assess outcomes from the implementation and share results through future peer-reviewed publications and national scientific forums.

Stay tuned for more such updates on Digital Health News